2 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Pegcrisantaspase: new trials by email Literature Review of Pegcrisantaspase trials Research Report on Pegcrisantaspase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar) pegcrisantaspase - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Terminated | Jazz Pharmaceuticals | 4 | 2014-09-01 | 2017-04-04 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blast Crisis (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic, T-Cell (1)
Jazz Pharmaceuticals (1) · M.D. Anderson Cancer Center (1)
United States (2)
Roman Skowronski, MD, PhD (1) · Tapan M Kadia (1)